within Pharmacolibrary.Drugs.ATC.A;

model A09AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Diastase is a mixture of amylolytic enzymes primarily derived from malt or pancreas, used to aid the digestion of starches in cases of digestive disorders such as dyspepsia, pancreatic insufficiency, or other conditions with impaired carbohydrate digestion. It is used as a digestive aid and was more common in older pharmaceutical preparations. Diastase is not widely used as a prescription drug in current medical practice and largely replaced by more standardized enzyme mixtures.</p><h4>Pharmacokinetics</h4><p>No published literature with specific pharmacokinetic parameters for diastase (A09AA01) in human subjects could be found. As diastase is an enzyme mixture administered orally to act locally in the gastrointestinal tract and not designed for systemic absorption, meaningful systemic pharmacokinetic parameters are typically not reported or not relevant.</p><h4>References</h4><ol><li><p>Williamson, G (2013). Possible effects of dietary polyphenols on sugar absorption and digestion. <i>Molecular nutrition &amp; food research</i> 57(1) 48–57. DOI:<a href=&quot;https://doi.org/10.1002/mnfr.201200511&quot;>10.1002/mnfr.201200511</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23180627/&quot;>https://pubmed.ncbi.nlm.nih.gov/23180627</a></p></li><li><p>Pieper-Bigelow, C, et al., &amp; Levitt, MD (1990). Where does serum amylase come from and where does it go?. <i>Gastroenterology clinics of North America</i> 19(4) 793–810. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1702756/&quot;>https://pubmed.ncbi.nlm.nih.gov/1702756</a></p></li><li><p>Balaich, J, et al., &amp; Donia, MS (2021). The human microbiome encodes resistance to the antidiabetic drug acarbose. <i>Nature</i> 600(7887) 110–115. DOI:<a href=&quot;https://doi.org/10.1038/s41586-021-04091-0&quot;>10.1038/s41586-021-04091-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34819672/&quot;>https://pubmed.ncbi.nlm.nih.gov/34819672</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A09AA01;
